期刊文献+

同时包载孕二烯酮和炔雌醇的PLGA微球的制备 被引量:2

Preparation of the PLGA microspheres loaded with both gestodene and ethinyl estradiol
下载PDF
导出
摘要 目的探索制备皮下注射用孕二烯酮/炔雌醇复方微球的可行性。方法以乳酸-羟基乙酸共聚物共聚物(PLGA)为载体材料,孕二烯酮、炔雌醇为模型药物,采用乳化溶剂挥发法制备皮下注射用复方微球,观察微球表面形态,检测所制微球的稳定性,检测微球的有机溶剂残留和体外释放特性。结果所得微球中孕二烯酮和炔雌醇的包封率分别为(69.9±6.6)%和(60.5±1.5)%;微球形态良好,粒径分布窄,平均粒径为(65.62±4.56)μm;微球中有机溶剂残留为(154.84±16.84)mg.L-1;体外释放过程中,2种药物能够持续稳定释放30 d,两药的体外释放行为符合Weibull方程,孕二烯酮和炔雌醇的释药方程分别为:ln[ln1/(1-F(t)]=0.625 8lnt-1.826(r=0.992 1)和:ln[ln1/(1-F(t)]=0.855 2lnt-2.850 1(r=0.991 4);制备的微球在高温、光照条件下均不稳定,在常温下长时间放置也不稳定,但在避光冷藏条件下稳定。结论所用制备工艺稳定,微球包封率较高,粒度均匀,有机溶剂残留符合国家标准,释药平稳,释药时间较长,可以进行进一步的体内研究。 Objective To study the practicability for the preparation of subcutaneous injected microspheres loaded with gestodene and ethinyl estradiol. Methods Using poly(d, 1-1actide-co-glycolide) (PLGA) as carrier material, gestodene and ethinyl estradiol as model drugs, injected microspheres were prepared through emulsion-evaporation method. The resulted microspheres were observed, and the stability, organic solvent residue and release behavior were also investigated. Results The loading efficiency of gestodene and ethinyl estradiol were (69.9 ± 6.6) % and (60.5 ± 1.5) %, respectively. The microspheres were well sphere-shaped, and the particle size distribution was very narrow, and the mean particle size was (65.62 ± 4.56)μm. As a result of the release testing, the release process of both the drugs could last 30 days, and the release behaviors were qualified for Weibull equation, which should be In (ln1/( 1-F ( t )) = 0. 6258lnt-1. 826 ( R^2 = 0. 992 1 ) and ln(ln1/(1-F(t ) ) = 0. 85521nt-2. 8501 (R^2 = 0. 991 4), respectively. The prepared microspheres were not stable when they were stored at high temperature and lighting condition for a long period, neither for long time storage in room temperature, but stable in cool and dark place. Conclusions The preparation condition is stable;the loading efficiency is relatively high;particle size is uniform; the organic residue is qualified for the national standard; release behavior is stable and the process is quite long. The further study should be carried on
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2008年第12期948-953,共6页 Journal of Shenyang Pharmaceutical University
关键词 乳酸-羟基乙酸共聚物 孕二烯酮 炔雌醇 微球制备 体外释放 PLGA-gestodene gestodene ethinyl estradiol microsphere preparation release in virto
  • 相关文献

参考文献7

  • 1TANEEPANICHSKUL S, KRIENGSINYOT R, JAISAMRARN U. A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene(Meliane) and 30 μg ethinylestradio1/75 μg gestodene(Gynera(r) ) [ J ]. Contraception, 2002, 66: 407 - 409.
  • 2SEGAL S J. Liability concerns in contraceptive research and development[J]. Int J Gynecol Obstet, 1999, 67: 141 - 151.
  • 3毕殿洲.药剂学:第四版[M].北京:人民卫生出版社,1999:461.
  • 4SINHA V R, AMAN T. Biodegradable microspheres for protein delivery[J ]. J Controlled Release, 2003, 90 (2) : 261 - 280.
  • 5RAJAN K V, SANJAY G. Current status of drug delivery technologies and future directions[ J ]. Pharm Technol On-Line, 2001,25(1):1- 14.
  • 6SANDERS L M, MCRAE G I, VITALE K M, et al. Controlled delivery of an LHRH analogue from biodegradable injectable microspheres [ J ]. J Controlled Release, 1985, 2 : 187.
  • 7SANDERS L M, KELL B A, MCREA G I, et al. Prolonged controlled-release of Nafareline, a luteinizing hormone-release hormone analogue, from biodegradable polymeric implants:influence of composition and molecular weight of polymer[J]. J Pharm Sci, 1986, 75:356.

共引文献1

同被引文献23

  • 1高艳丽,肖琰,梁金英,朱萱萱,李瑛,刘建平.孕二烯酮-炔雌醇双层贴剂的制备及体内外评价(英文)[J].中国药科大学学报,2009,40(5):416-420. 被引量:2
  • 2KISER PF1 ,JOHNSON TJ,CLARK JT. State of the art in intrav- aginal ring technology for topical prophylaxis of HIV infection [J]. AIDS Rev,2012,14(1) :62 -77.
  • 3LETE I, DUENAS JL, ESPLUGUES JV. Is the vagina an ade- quate route for the administration of hormonal contraceptives? [J]. Curr Drug Metab ,2010 ,11( 10 ) :839 - 849.
  • 4KEMS J, DARNEY P. Vaginal ring contraception [ J]. Contra- ception,2011,83 ( 2 ) : 107 - 115.
  • 5ELKIND-HIRSCH KE. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive[J]. Contraception, 2007,76 ( 5 ) : 348 - 356.
  • 6BENAGIANO G,GABELNICK H. Contraceptive devices:intrav- aginal and intrauterine delivery systems[ J]. Expert Rev Med De- vices,2008,5 (5) :639 - 654.
  • 7SAY R, MANSOUR D. Contraceptive choice for young people [J]. J Fam Plana Reprod Health Care,2009,35(2) :81 -85.
  • 8MALCOLM RK,EDVWARDS KL. Advances in mierobicide vagi- nal rings[ J]. Antiviral Res ,2010,88 ( Suppl 1 ) : S30 - S39.
  • 9SAXENA BB, HAN YA, RATHNAM P, et al. Sustained release of microbicides by newly engineered vaginal rings [ J ]. AIDS, 2009,23(8) :917 -922.
  • 10RUMANDOR AC,STANFORD LA,TAYLOR LS. Effectsof poly- mer type and storage relative humidity on the kineticsof felodipine crystallization from amorphous solid dispersions[ J]. Pharm Res, 2009,26 ( 12 ) : 2599 - 2606.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部